Regression of lipodystrophy in HIV-infected patients under therapy with the new protease inhibitor atazanavir.
Haerter
Georg
G
Division of Infectious Diseases, Department of Internal Medicine, University Hospital and Medical Center, 89081 Ulm, Germany.
Manfras
Burkhard J
BJ
Mueller
Markus
M
Kern
Peter
P
Trein
Andreas
A
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D000069446:Atazanavir Sulfate; D005260:Female; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015497:HIV-1; D039682:HIV-Associated Lipodystrophy Syndrome / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*
D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D011725:Pyridines; D000069446:Atazanavir Sulfate